Abstract
The structure-based design of 1, 2, 3, 4-tetrahydroisoquinoline derivatives as selective DDR1 inhibitors is reported. One of the representative compounds, 6j, binds to DDR1 with a Kd value of 4.7 nM and suppresses its kinase activity with an IC50 value of 9.4 nM, but it is significantly less potent for a panel of 400 nonmutated kinases. 6j also demonstrated reasonable pharmacokinetic properties and a promising oral therapeutic effect in a bleomycin-induced mouse pulmonary fibrosis model.
Original language | English (US) |
---|---|
Pages (from-to) | 5911-5916 |
Number of pages | 6 |
Journal | Journal of Medicinal Chemistry |
Volume | 59 |
Issue number | 12 |
DOIs | |
State | Published - Jun 23 2016 |
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery